Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKinsey
Dow
Boehringer Ingelheim
Medtronic

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Dapagliflozin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00162305 ↗ A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed Bristol-Myers Squibb Phase 2 2005-04-01 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00162305 ↗ A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed AstraZeneca Phase 2 2005-04-01 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00263276 ↗ A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus Completed Bristol-Myers Squibb Phase 2 2005-12-01 The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
NCT00263276 ↗ A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus Completed AstraZeneca Phase 2 2005-12-01 The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dapagliflozin

Condition Name

Condition Name for Dapagliflozin
Intervention Trials
Type 2 Diabetes Mellitus 55
Diabetes Mellitus, Type 2 51
Type 2 Diabetes 46
Heart Failure 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dapagliflozin
Intervention Trials
Diabetes Mellitus 187
Diabetes Mellitus, Type 2 179
Heart Failure 39
Diabetes Mellitus, Type 1 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dapagliflozin

Trials by Country

Trials by Country for Dapagliflozin
Location Trials
Canada 188
Mexico 103
United Kingdom 95
China 64
India 62
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dapagliflozin
Location Trials
Texas 72
California 59
Florida 53
New York 45
North Carolina 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dapagliflozin

Clinical Trial Phase

Clinical Trial Phase for Dapagliflozin
Clinical Trial Phase Trials
Phase 4 129
Phase 3 92
Phase 2/Phase 3 14
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dapagliflozin
Clinical Trial Phase Trials
Completed 160
Recruiting 85
Not yet recruiting 61
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dapagliflozin

Sponsor Name

Sponsor Name for Dapagliflozin
Sponsor Trials
AstraZeneca 160
Bristol-Myers Squibb 49
The University of Texas Health Science Center at San Antonio 13
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dapagliflozin
Sponsor Trials
Other 353
Industry 268
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Merck
Dow
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.